Flash Finance

Sun Pharmaceutical Industries LimitedSUNPHARMACorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹1,758.80
MCap ₹421,995 Cr · P/E 141.0
Sun Pharmaceutical Industries Limited — Stock analysis & AI research Sun Pharmaceutical Industries Limited — Multibagger AI analysis Sun Pharmaceutical Industries Limited — Seasonality — best & worst months Sun Pharmaceutical Industries Limited — Technical indicators & charts Sun Pharmaceutical Industries Limited — Technical setup — score, trend, support & resistance Sun Pharmaceutical Industries Limited — Double Top pattern broken down ↓ Sun Pharmaceutical Industries Limited — Live exchange announcements
📋 High ROCE Stocks📋 High Operating Margin Stocks📋 High Interest Coverage Stocks📋 Low Debt Stocks📋 Large Cap Stocks List ⚖️ vs Zydus Lifesciences⚖️ vs Laurus Labs 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹5,741 Cr
Sales · Jun 2026
+2.5% YoY
₹1,964 Cr
Operating Profit · Jun 2026
+3.9% YoY
34.2%
OPM % · Jun 2026
+1.2% YoY
₹1,115 Cr
Net Profit · Jun 2026
+48.0% YoY
₹4.60
EPS · Jun 2026
+48.4% YoY

📝 Sun Pharmaceutical Industries Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Sun Pharmaceutical Industries Limited reported revenue of ₹5,741 crore for the quarter ended June 2026 (Q1 FY27), up 2.5% from ₹5,602 crore in the same quarter last year, and up 16.6% sequentially over the March 2026 quarter.

Net profit rose 48.0% year-on-year to ₹1,115 crore, from ₹754 crore. Earnings per share (EPS) came in at ₹4.60.

Operating profit stood at ₹1,964 crore — an operating margin (OPM) of 34.2%, compared with 33.8% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Sun Pharmaceutical Industries Limited posted revenue of ₹20,762 crore, a decline of 9.7% over FY25, with a net profit of ₹2,632 crore (down 38.5% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹20,901 crore with a net profit of ₹2,994 crore.

Valuation snapshot

At the current price of ₹1,758.80, SUNPHARMA has a market capitalisation of ₹421,995 crore and a trailing P/E of about 141.0.

Within the Drug Manufacturers - Specialty & Generic industry, it is the largest of the 31 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 52.68%, foreign institutional investors (FIIs) 14.36%, domestic institutional investors (DIIs) 22.27%, public shareholders 10.70% of Sun Pharmaceutical Industries Limited.

Promoter holding slipped from 54.48% to 52.68% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹421,995 Cr
Current Price ?
₹1,758.8
P/E ?
140.96above ind
Industry P/E ?
35.00
P/B ?
18.86
P/S ?
20.19
P/FCF ?
84.62
Enterprise Value ?
₹435,600 Cr
EV/EBITDA ?
69.86
PEG ?
N/A
Earnings Yield ?
1.1%
Dividend Yield ?
0.91%
Profitability & Returns
Sales (TTM) ?
₹20,901 Cr
OPM ?
29.8%
Profit after tax (TTM) ?
₹2,994 Cr
EPS (TTM) ?
₹12.48
ROCE ?
15.0%
ROE ?
13.4%
ROA ?
7.0%
Growth
Sales — latest qtr ?
₹5,741 Cr
PAT — latest qtr ?
₹1,115 Cr
YoY qtr sales growth ?
2.5%
YoY qtr profit growth ?
48.0%
Sales growth (3y) ?
0%
Sales growth (5y) ?
8%
Profit growth (3y) ?
-4%
Profit growth (5y) ?
27%
Financial Health
Debt ?
₹13,605 Cr
Debt to Equity ?
0.61
Interest Coverage ?
5.2
Current Ratio ?
N/A
Ownership
Promoter holding ?
52.68%
Change in promoter holding ?
-1.80%
Pledged percentage ?
N/A
Market
Return 3 months ?
-9.0%
Return 6 months ?
5.0%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 4,6465,9484,4665,0965,0745,6394,4985,1286,1927,1865,6024,5485,6884,9245,741 +2.5% +16.6%
Operating Profit 9992,3619491,3861,3591,8947611,3391,7032,9891,8911,1841,7591,3291,964 +3.9% +47.8%
Other Income 68120164107771198386681321047318063140 +35.2% +122.5%
Interest 131161158194215218216244216217223248244217278 +24.7% +28.3%
Depreciation 430412415393400393370286291292299336339326308 +3.0% -5.5%
Profit Before Tax 506-1,0303909077511,4022588961,2652,6121,1856721,0978491,486 +25.5% +75.1%
Net Profit 487-1,0213818897218682388631,1812,0007545647056091,115 +48.0% +83.1%
EPS 2.00-4.301.603.703.003.601.003.604.908.303.102.402.902.544.60 +48.4% +81.1%
OPM % 21.5% 39.7% 21.2% 27.2% 26.8% 33.6% 16.9% 26.1% 27.5% 41.6% 33.8% 26.0% 30.9% 27.0% 34.2% +1.2% +26.7%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹23,003 Cr ₹20,762 Cr ₹20,901 Cr -9.7%
Operating Profit ₹6,793 Cr ₹6,162 Cr ₹6,235 Cr -9.3%
OPM % 29.53% 29.68% 29.83% +0.5%
NPM % 18.62% 12.68% 14.32% -31.9%
Other Income ₹369 Cr ₹419 Cr ₹456 Cr +13.5%
Depreciation ₹1,238 Cr ₹1,300 Cr ₹1,309 Cr +5.0%
Interest ₹893 Cr ₹933 Cr ₹988 Cr +4.4%
EBIT ₹5,554 Cr ₹4,862 Cr ₹4,927 Cr -12.5%
PBT ₹5,031 Cr ₹3,803 Cr ₹4,104 Cr -24.4%
Tax — ₹931 Cr ₹871 Cr —
Net Profit ₹4,283 Cr ₹2,632 Cr ₹2,994 Cr -38.5%
EPS ₹17.80 ₹10.94 ₹12.44 -38.5%
Material Cost ₹6,050 Cr ₹4,304 Cr ₹4,423 Cr -28.9%
Employee Cost ₹2,608 Cr ₹2,183 Cr ₹2,299 Cr -16.3%
Extraordinary Items — ₹-29 Cr ₹290 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 240240240240 +0.0%
Reserves 23,50823,45424,10022,131 -8.2%
Borrowings 7,79111,22711,13813,605 +22.1%
Other Liabilities 9,4486,1437,7967,084 -9.1%
Total Liabilities 40,98741,06543,27343,060 -0.5%
Fixed Assets 8,7127,7376,9897,860 +12.5%
CWIP 853766939652 -30.6%
Investments 12,61312,43012,41012,952 +4.4%
Other Assets 18,81020,13222,93621,596 -5.8%
Total Assets 40,98741,06543,27343,060 -0.5%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 507-2924,1996,501 +54.8%
Cash from Investing Activity -686-265-202-1,381 -583.7%
Cash from Financing Activity 169474-3,831-5,230 -36.5%
Net Cash Flow -9-84166-110 -166.3%
Free Cash Flow -447-1,0273,5454,987 +40.7%
CFO/OP 15%1%66%112% +69.7%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 125159186179 -3.8%
Inventory Days 240223231287 +24.2%
Days Payable 188171210236 +12.4%
Cash Conversion Cycle 177211207230 +11.1%
Working Capital Days 131182-5171 +3520.0%
ROCE % 17%13%17%15% -11.8%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 54.48%54.48%54.48%54.48%52.68% -3.3%
FIIs 17.26%16.55%16.12%15.94%14.36% -9.9%
DIIs 19.38%20.12%20.72%21.00%22.27% +6.0%
Government 0.11%0.11%0.11%0.11%— —
Public 8.76%8.72%8.57%8.48%10.70% +26.2%
No. of Shareholders 7,23,7707,43,8777,10,9006,90,9577,14,266 +3.4%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Sun Pharmaceutical Industries Limited's revenue in Q1 FY27?
Sun Pharmaceutical Industries Limited reported revenue of ₹5,741 crore for the quarter ended June 2026 (Q1 FY27), up 2.5% from ₹5,602 crore in the same quarter last year, and up 16.6% sequentially over the March 2026 quarter.
What was Sun Pharmaceutical Industries Limited's net profit in Q1 FY27?
Net profit rose 48.0% year-on-year to ₹1,115 crore, from ₹754 crore. Earnings per share (EPS) came in at ₹4.60.
What is SUNPHARMA's market capitalisation and P/E ratio?
At the current price of ₹1,758.80, SUNPHARMA has a market capitalisation of ₹421,995 crore and a trailing P/E of about 141.0.
Who owns Sun Pharmaceutical Industries Limited? (shareholding pattern)
As of Sep 2026, promoters held 52.68%, foreign institutional investors (FIIs) 14.36%, domestic institutional investors (DIIs) 22.27%, public shareholders 10.70% of Sun Pharmaceutical Industries Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI